These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 17873184)

  • 21. Bloodstream infections due to Micrococcus spp and intravenous epoprostenol.
    Valdivia-Arenas MA
    Infect Control Hosp Epidemiol; 2009 Dec; 30(12):1237. PubMed ID: 19888847
    [No Abstract]   [Full Text] [Related]  

  • 22. Treprostinil for the treatment of pulmonary arterial hypertension.
    Torres F; Rubin LJ
    Expert Rev Cardiovasc Ther; 2013 Jan; 11(1):13-25. PubMed ID: 23259441
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Conversion to bosentan from prostacyclin infusion therapy in pulmonary arterial hypertension: a pilot study.
    Steiner MK; Preston IR; Klinger JR; Criner GJ; Waxman AB; Farber HW; Hill NS
    Chest; 2006 Nov; 130(5):1471-80. PubMed ID: 17099026
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Epoprostenol sodium for treatment of pulmonary arterial hypertension.
    Saito Y; Nakamura K; Akagi S; Sarashina T; Ejiri K; Miura A; Ogawa A; Matsubara H; Ito H
    Vasc Health Risk Manag; 2015; 11():265-70. PubMed ID: 25999730
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A case series of patients with severe pulmonary hypertension receiving an implantable pump for intravenous prostanoid therapy.
    Ewert R; Halank M; Bruch L; Ghofrani HA
    Am J Respir Crit Care Med; 2012 Dec; 186(11):1196-8. PubMed ID: 23204382
    [No Abstract]   [Full Text] [Related]  

  • 26. Advances in prostacyclin therapy for pulmonary arterial hypertension.
    Eells PL
    Crit Care Nurse; 2004 Apr; 24(2):42-8, 50-4. PubMed ID: 15098310
    [No Abstract]   [Full Text] [Related]  

  • 27. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial.
    Simonneau G; Barst RJ; Galie N; Naeije R; Rich S; Bourge RC; Keogh A; Oudiz R; Frost A; Blackburn SD; Crow JW; Rubin LJ;
    Am J Respir Crit Care Med; 2002 Mar; 165(6):800-4. PubMed ID: 11897647
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Prostacyclin and iloprost in aerosol form in severe pulmonary hypertension].
    Olschewski H; Walmrath D; Schermuly R; Ghofrani HA; Grimminger F; Seeger W
    Pneumologie; 1998 Jan; 52(1):3-7. PubMed ID: 9540363
    [No Abstract]   [Full Text] [Related]  

  • 29. Treprostinil for the treatment of pulmonary arterial hypertension in patients with New York Heart Association class II-IV symptoms.
    Herald N; Laliberte K
    Pharmacotherapy; 2006 Aug; 26(8):1203; discussion 1203-4. PubMed ID: 16863500
    [No Abstract]   [Full Text] [Related]  

  • 30. Safety and efficacy of transition from subcutaneous treprostinil to oral sildenafil in patients with pulmonary arterial hypertension.
    Keogh AM; Jabbour A; Weintraub R; Brown K; Hayward CS; Macdonald PS
    J Heart Lung Transplant; 2007 Nov; 26(11):1079-83. PubMed ID: 18022071
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Current status and future prospect of prostacyclin therapy for pulmonary hypertension--intravenous, subcutaneous, inhaled and oral PGI2 derivatives].
    Saji T; Nakayama T; Ishikita T; Matsuura H
    Nihon Rinsho; 2001 Jun; 59(6):1132-8. PubMed ID: 11411125
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Subcutaneous treprostinil in pulmonary arterial hypertension: Practical considerations.
    Mathier MA; McDevitt S; Saggar R
    J Heart Lung Transplant; 2010 Nov; 29(11):1210-7. PubMed ID: 20855220
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Transition from intravenous epoprostenol to oral or subcutaneous therapy in pulmonary arterial hypertension: a retrospective case series and systematic review.
    Park K; Ostrow D; Levy RD; Swiston J
    Can Respir J; 2011; 18(3):157-62. PubMed ID: 21766080
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of long-term subcutaneous treprostinil sodium therapy in pulmonary hypertension.
    Lang I; Gomez-Sanchez M; Kneussl M; Naeije R; Escribano P; Skoro-Sajer N; Vachiery JL
    Chest; 2006 Jun; 129(6):1636-43. PubMed ID: 16778286
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The "bouncing" catheter.
    Malaczynska-Rajpold K; Kurzyna M; Koteja A; Torbicki A; Mularek-Kubzdela T
    Cardiol J; 2016; 23(5):552-553. PubMed ID: 27723062
    [No Abstract]   [Full Text] [Related]  

  • 36. Ondansetron eliminates nausea and vomiting associated with prostacyclin in a patient awaiting lung transplantation.
    Lawhorn S; Lawhorn CD; Davison C
    J Heart Lung Transplant; 1997 Apr; 16(4):472-3. PubMed ID: 9154961
    [No Abstract]   [Full Text] [Related]  

  • 37. Plasma brain natriuretic peptide as a parameter to assess efficacy of continuous intravenous infusion of prostacyclin (epoprostenol) to treat severe primary pulmonary hypertension: a case report.
    Wakaumi M; Shiga T; Nozaki K; Fujiu K; Shimaya K; Ishizuka N; Matsuda N; Kasanuki H
    Heart Vessels; 2000; 15(3):144-6. PubMed ID: 11289503
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Add-on therapy with subcutaneous treprostinil for refractory pediatric pulmonary hypertension.
    Levy M; Celermajer DS; Bourges-Petit E; Del Cerro MJ; Bajolle F; Bonnet D
    J Pediatr; 2011 Apr; 158(4):584-8. PubMed ID: 21035821
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Oral prostacyclin therapy for pulmonary arterial hypertension: another step forward.
    Waxman AB
    Circulation; 2013 Feb; 127(5):563-5. PubMed ID: 23307828
    [No Abstract]   [Full Text] [Related]  

  • 40. [Role of prostacyclin and its derivatives in the treatment of pulmonary arterial hypertension].
    Osvaldo Cáneva J; Ossés JM
    Medicina (B Aires); 2003; 63(3):233-6. PubMed ID: 12876911
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.